RxDoctor Payments Data

Christopher Kampas, MD

Family Medicine · Mesquite, TXNPI 1154369536

Payments from drug & device makers

$1,658in general payments, 2019–2025

Across 102 payments — averaging $16.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$342
  • Amarin Pharma, Inc.$183
  • Novo Nordisk$137
  • Abbott$129
  • Lilly USA, LLC$117
  • Sanofi-aventis U.S. LLC$85
  • plus $665 from 17 others

What the payments were for

  • Food & beverage$1,64799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,658 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$65,032
Medicare patients
157
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$40,765
FarxigaDapagliflozin Propanediol38$29,743
JardianceEmpagliflozin27$29,213
TrulicityDulaglutide12$25,768
MounjaroTirzepatide22$22,913
EliquisApixaban32$20,860
MyrbetriqMirabegron16$13,806
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,078
Levothyroxine Sodium158$2,868
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$2,280
SynthroidLevothyroxine Sodium17$2,100
Atorvastatin Calcium224$1,769
Gabapentin80$1,705
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide36$1,267
Olmesartan Medoxomil23$1,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$117$48,68134 claims
Novo NordiskOzempic$137$40,76531 claims
AstraZenecaFarxiga$342$29,74338 claims
Boehringer IngelheimJardiance$16$29,21327 claims
PfizerEliquis$40$20,86032 claims
Astellas Pharma US IncMyrbetriq$18$13,80616 claims
GSKTrelegy Ellipta$81$10,07814 claims
AbbVieSynthroid$38$2,10017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mesquite

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →